EASI Score Calculator
Calculate the Eczema Area and Severity Index (EASI) score to assess atopic dermatitis severity.
Select severity (0-3) and area score (0-6) for each body region. Score updates automatically.
Head / Neck
Upper Limbs
Trunk
Lower Limbs
What Is the EASI Score?
The Eczema Area and Severity Index (EASI) is a validated clinical tool used to measure the extent and severity of atopic dermatitis. It quantifies both the physical signs of eczema and the body surface area affected, producing a single numerical score that helps clinicians track disease progression and treatment response over time.
Unlike subjective assessments, the EASI score provides a standardized, reproducible metric. It is widely used in clinical trials and dermatology practice to evaluate treatment efficacy and guide therapeutic decisions.
How the EASI Score Is Calculated
The EASI scoring system evaluates four key signs of atopic dermatitis across four body regions. Each sign is rated for severity, then weighted by the percentage of skin affected in that region.
Severity Components
Four clinical signs are assessed on a scale of 0 to 3:
- Erythema (E) — redness or inflammation
- Induration/Papulation (I) — thickening or raised bumps
- Excoriation (Ex) — scratch marks or broken skin
- Lichenification (L) — leathery, thickened skin from chronic scratching
Each sign is scored: 0 (none), 1 (mild), 2 (moderate), or 3 (severe).
Body Regions and Area Scores
The body is divided into four regions, each assigned a specific multiplier based on its proportion of total body surface area:
- Head and Neck — multiplier 0.1 (10% of body surface)
- Upper Limbs — multiplier 0.2 (20%)
- Trunk — multiplier 0.3 (30%)
- Lower Limbs — multiplier 0.4 (40%)
For each region, the percentage of skin affected by eczema is estimated in 1% increments. This area score is converted to a 0 to 6 scale: 0 (0%), 1 (1–9%), 2 (10–29%), 3 (30–49%), 4 (50–69%), 5 (70–89%), 6 (90–100%).
The Formula
For each body region, the regional subscore is calculated as:
(E + I + Ex + L) × Area Score × Region Multiplier
The total EASI score is the sum of all four regional subscores, ranging from 0 to 72.
Interpreting EASI Scores
Higher scores indicate more severe atopic dermatitis. The following severity categories are commonly used in clinical practice:
| EASI Score | Severity |
|---|---|
| 0 | Clear |
| 0.1 – 1.0 | Almost clear |
| 1.1 – 7.0 | Mild |
| 7.1 – 21.0 | Moderate |
| 21.1 – 50.0 | Severe |
| 50.1 – 72.0 | Very severe |
These thresholds are guidelines. Treatment decisions should always consider additional factors such as symptom burden, quality of life impact, and patient history.
Practical Use Cases
The EASI score serves several important functions in dermatology:
- Baseline assessment — establishing initial disease severity before treatment
- Treatment monitoring — tracking response to topical therapies, systemic medications, or biologics
- Clinical trials — providing a standardized endpoint for evaluating new treatments
- Telemedicine — enabling remote assessment when in-person examination is limited
Limitations and Considerations
The EASI score has several important limitations to be aware of:
- It does not capture subjective symptoms like itching or sleep disturbance. These are assessed separately with tools like the Pruritus NRS or POEM.
- Area estimation can vary between assessors, introducing inter-rater variability.
- The score may not fully reflect disease impact in darker skin types, where erythema can be harder to evaluate visually.
- EASI is designed for atopic dermatitis and is not validated for other eczematous conditions.
For comprehensive disease assessment, EASI is best used alongside patient-reported outcome measures and quality of life questionnaires.
Frequently Asked Questions
What is the difference between EASI and SCORAD?
Both are validated tools for assessing atopic dermatitis severity, but they differ in structure. EASI focuses exclusively on objective signs (erythema, induration, excoriation, lichenification) and area extent. SCORAD includes these objective components plus subjective symptoms (itch and sleep loss) and uses different area weighting. EASI is more commonly used in clinical trials, while SCORAD is often preferred in clinical practice for its inclusion of patient-reported symptoms.
Can the EASI score be used for children?
Yes. EASI has been validated for use in children as young as 6 months. The scoring methodology remains the same, though the body surface area proportions differ slightly in infants compared to adults. The same severity thresholds are generally applied across age groups.
How often should EASI be assessed?
Frequency depends on the clinical context. In clinical trials, assessments may occur every 2 to 4 weeks. In routine practice, reassessment at each follow-up visit (typically every 4 to 12 weeks) is reasonable to track treatment response and adjust therapy as needed.
What is a clinically meaningful change in EASI score?
A reduction of 50% or more from baseline (EASI-50) is generally considered a clinically meaningful improvement. EASI-75 and EASI-90 are increasingly used as stringent efficacy endpoints in clinical trials, particularly for biologic therapies.
Does the EASI score account for itch?
No. EASI measures only visible physical signs of eczema. Itch (pruritus) is a separate domain and should be assessed using dedicated tools such as the Peak Pruritus Numerical Rating Scale (PP-NRS) or the Patient-Oriented Eczema Measure (POEM), which includes itch-related questions.